Recent News

• 05.12.2025 - Relmada Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
• 05.12.2025 - Relmada Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
• 05.08.2025 - Relmada Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025
• 04.28.2025 - Relmada Therapeutics Presents Positive Initial Phase 2 NDV-01 Data at AUA2025
• 04.28.2025 - Relmada Therapeutics Presents Positive Initial Phase 2 NDV-01 Data at AUA2025
• 04.27.2025 - UPDATE -- Relmada Therapeutics To Present NDV-01 Data at AUA2025
• 04.27.2025 - UPDATE -- Relmada Therapeutics To Present NDV-01 Data at AUA2025
• 04.24.2025 - Relmada Therapeutics to Host KOL Event on Phase 2 NDV-01 Data
• 04.14.2025 - UPDATE -- Relmada Therapeutics To Present NDV-01 Data at AUA2025
• 04.14.2025 - UPDATE -- Relmada Therapeutics To Present NDV-01 Data at AUA2025

Recent Filings

• 05.01.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 04.28.2025 - 8-K Current report
• 04.28.2025 - 424B5 Prospectus [Rule 424(b)(5)]
• 04.28.2025 - EX-99.1 EX-99.1
• 04.11.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 04.11.2025 - DEF 14A Other definitive proxy statements
• 03.27.2025 - 8-K Current report